Citations

Clear

6273 citation(s) found for "To, Andrew".

2018 International Consensus Meeting on Musculoskeletal Infection: Research Priorities from the General Assembly Questions
Schwarz, Edward M. , Gehrke, Thorsten , Aiyer, Amiethab A. , Battenberg, Andrew K. , Brown, Scot , Callaghan, John J. , Egol, Kenneth A. , Garrigues, Grant E. , Ghert, Michelle , Goswami, Karan , Hammound, Sommer, McLaren, A. C. , Mont, Michael A. , Namdari, Surena , Obremskey, William T. , O’Toole, Robert V. , Raikin, Steven M. , Restrepo, Camilo , Ricciardi, Benjamin F. , Saeed, Kordo , Shohat, Noam , Tan, Timothy L. , Thirukumaran, Caroline P. , Winters, Brian S., Sanchez-Sotelo, Joaquin, Schwarz, Edward M , Parvizi, Javad , Gehrke, Thorsten A. , Çıtak, Mustafa , Green, Andrew , Kates, Stephen L. , Sánchez‐Sotelo, Joaquín

Mayo Clinic

Journal of Orthopaedic Research | April 12, 2019 | Volume: 37 | Issue: 5 | Pages: 997-1006

10.1002/jor.24293 | PMID 30977537 Get It

ABSTRACT Musculoskeletal infections (MSKI) remain the bane of orthopedic surgery, and result in grievous illness and inordinate costs that threaten healthcare systems. As prevention, diagnosis, and treatment has remained largely unchanged over the last 50 years, a 2nd International Consensus Meeting on Musculoskeletal Infection (ICM 2018, https://icmphilly.com ) was completed. Questions pertaining to all areas of MSKI were extensively researched to prepare recommendations, which were discussed and voted on by the delegates using the Delphi methodology. The questions, including the General Assembly (GA) results, have been published ( GA questions ). However, as critical outcomes include: (i) incidence and cost data that substantiate the problems, and (ii) establishment of research priorities; an ICM 2018 research workgroup (RW) was assembled to accomplish these tasks. Here, we present the result of the RW consensus on the current and projected incidence of infection, and the costs per patient, for all orthopedic subspecialties, which range from 0.1% to 30%, and $17,000 to $150,000. The RW also identified the most important research questions. The Delphi methodology was utilized to initially derive four objective criteria to define a subset of the 164 GA questions that are high priority for future research. Thirty‐eight questions (23% of all GA questions) achieved the requisite > 70% agreement vote, and are highlighted in this Consensus article within six thematic categories: acute versus chronic infection, host immunity, antibiotics, diagnosis, research caveats, and modifiable factors. Finally, the RW emphasizes that without appropriate funding to address these high priority research questions, a 3rd ICM on MSKI to address similar issues at greater cost is inevitable.
Accelerated gastric emptying is associated with improved aspiration efficiency in obesity
Storm, Andrew C. , Vargas, Eric J , Bazerbachi, Fateh , Abu Dayyeh, Barham K, Storm, Andrew C , Vargas, Eric J. , Dayyeh, Barham K. Abu

Mayo Clinic

BMJ Open Gastroenterology | April 10, 2019 | Volume: 6 | Issue: 1 | Pages: e000273

10.1136/bmjgast-2019-000273 | PMID 31139425 Get It

Background The overall effectiveness of aspiration therapy (AT) for obesity relies on optimal aspiration timing after a meal, which can vary depending on a patient’s rate of gastric emptying (GE). Our aim was to identify if baseline GE rates were associated with differences in aspiration efficiency (AE). Methods Subjects from an ongoing AT clinical trial were enrolled in this study. AE was calculated as the absolute gastric residual and calories aspirated at 20 and 40 min. Participants were then divided by baseline GE rate into two groups (slow vs fast). Wilcoxon rank-sum test was used to compare AE at 20 and 40 min between the groups. Exploratory linear regression was used to assess relationship between GE and AE. Results 7 patients (85% female) were coenrolled in the study. Mean age and body mass index were 39.8±9.44 and 43±5, respectively. AE did not significantly differ between the 20 and 40 min time points for the group as a whole (34.3% vs 36.9%; p>0.5). However, those with fast GE aspirated more calories than those with slow GE (20 min: 200 kcal vs 72.5 kcal; 40 min: 154 kcal vs 63 kcal) (p=0.05). On linear regression, delayed GE was associated with poorer aspiration (20 min: β=−107 calories; p=0.019; R2=0.7). 4/7 patients had significant differences in residual/caloric aspiration across the two time points. Conclusion Patients undergoing AT may benefit from a GE test to optimise their AE. Paradoxically faster GE times saw better aspiration. Prospective studies are revealing a personalised approach to obesity.
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303
Bartlett, Nancy L. , Wilson, Wyndham H. , Pederson, Levi , Polley, Mei‐Yin C. , Pitcher, Brandelyn N., Cheson, Bruce D. , Friedberg, Jonathan W. , Staudt, Louis M. , Wagner‐Johnston, Nina D. , Blum, Kristie A. , Reddy, Nishitha , Chang, Julie , Chadburn, Amy , Mathew, Susan , Fisher, Richard I., Richards, Kristy L. , Leonard, John P. , Bartlett, Nancy L , Jung, Sin‐Ho , Hsi, Eric D. , Maurer, Matthew J. , Kahl, Brad S. , Abramson, Jeremy S. , Winter, Jane N. , Gopal, Ajay K. , Schöder, Heiko , Zelenetz, Andrew D.

Mayo Clinic

Journal of Clinical Oncology | April 2, 2019 | Volume: 37 | Issue: 21 | Pages: 1790-1799

10.1200/jco.18.01994 | PMID 30939090 Get It

PURPOSE Alliance/CALGB 50303 (NCT00118209), an intergroup, phase III study, compared dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab (DA-EPOCH-R) with standard rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) as frontline therapy for diffuse large B-cell lymphoma. PATIENTS AND METHODS Patients received six cycles of DA-EPOCH-R or R-CHOP. The primary objective was progression-free survival (PFS); secondary clinical objectives included response rate, overall survival (OS), and safety. RESULTS Between 2005 and 2013, 524 patients were registered; 491 eligible patients were included in the final analysis. Most patients (74%) had stage III or IV disease; International Prognostic Index (IPI) risk groups included 26% IPI 0 to 1, 37% IPI 2, 25% IPI 3, and 12% IPI 4 to 5. At a median follow-up of 5 years, PFS was not statistically different between the arms (hazard ratio, 0.93; 95% CI, 0.68 to 1.27; P = .65), with a 2-year PFS rate of 78.9% (95% CI, 73.8% to 84.2%) for DA-EPOCH-R and 75.5% (95% CI, 70.2% to 81.1%) for R-CHOP. OS was not different (hazard ratio, 1.09; 95% CI, 0.75 to 1.59; P = .64), with a 2-year OS rate of 86.5% (95% CI, 82.3% to 91%) for DA-EPOCH-R and 85.7% (95% CI, 81.4% to 90.2%) for R-CHOP. Grade 3 and 4 adverse events were more common ( P < .001) in the DA-EPOCH-R arm than the R-CHOP arm, including infection (16.9% v 10.7%, respectively), febrile neutropenia (35.0% v 17.7%, respectively), mucositis (8.4% v 2.1%, respectively), and neuropathy (18.6% v 3.3%, respectively). Five treatment-related deaths (2.1%) occurred in each arm. CONCLUSION In the 50303 study population, the more intensive, infusional DA-EPOCH-R was more toxic and did not improve PFS or OS compared with R-CHOP. The more favorable results with R-CHOP compared with historical controls suggest a potential patient selection bias and may preclude generalizability of results to specific risk subgroups.
Breaking tolerance with engineered class I antigen-presenting molecules
Parks, Christopher A. , Henning, Kalli R., Hansen, Michael J. , Keulen, Virginia P. Van , Reed, Brendan , Schrum, Adam G. , Gil, Diana , Kranz, David M. , Bordner, Andrew J., Barry, Michael A. , Pease, Larry R. , Pavelko, Kevin D. , Reed, Brendan K, Schrum, Adam G , Barry, Michael A , Stone, Jennifer D.

Mayo Clinic

Proceedings of the National Academy of Sciences | April 1, 2019 | Volume: 116 | Issue: 8 | Pages: 3136-3145

10.1073/pnas.1807465116 | PMID 30728302 Get It

Significance Provision of sufficient activating signals can drive self-tolerant T cells to cross-react on self-peptide-MHC in a breakdown of tolerance. This approach has been applied in the development of heteroclitic peptide vaccines, which retain sufficient similarity to self to allow reactivation of effector cells on unaltered self-epitopes but require detailed knowledge about the behavior of individual altered self-peptide antigens. We designed altered-self MHC mutant antigen-presenting molecules to drive CTL capable of cross-reacting on self-peptide-MHC and demonstrate the breaking of self-tolerance to defined and undefined self-antigens. These findings bear particular importance in the field of cancer immunotherapy in which breaking tolerance to weakly antigenic cancer-associated antigens is fundamental to vaccination strategies.
176 Hydrocelectomy Using a Minimally-invasive, Office-Based Approach
Ziegelmann, M., Alom, Manaf, Köhler, Thomas, Trost, Leonid Benjamin, Miller, Andrew S. , Kohler, T.

Mayo Clinic

The Journal of Sexual Medicine | March 29, 2019 | Volume: 16 | Issue: Supplement_1 | Pages: S88-S88

10.1016/j.jsxm.2019.01.185 Get It

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review
Anker, Markus S. , Holcomb, Richard , Muscaritoli, Maurizio , Haehling, Stephan von , Haverkamp, Wilhelm , Jatoi, Aminah , Morley, John E. , Strasser, Florian, Landmesser, Ulf , Landmesser, Ulf , Coats, Andrew J.S. , Anker, Stefan D.

Mayo Clinic

Journal of Cachexia, Sarcopenia and Muscle | March 28, 2019 | Volume: 10 | Issue: 1 | Pages: 22-34

10.1002/jcsm.12402 | PMID 30920776 Get It

Abstract Background Cachexia has significant impact on the patients' quality of life and prognosis. It is frequently observed in patients with cancer, especially in advanced stages, but prevalence data for the overall population are lacking. Good quality estimates of cancer cachexia in general and for each of the major cancer types would be highly relevant for potential treatment development efforts in this field. Both the USA and European Union (EU) have implemented special clinical development rules for such rare disorders what are called ‘orphan diseases’. The cut‐off level for a disease to be considered an orphan disease in the USA is 200 000 people (0.06% of the population) and EU is 5 per 10 000 people (0.05% of the population). Methods For this systematic review, we searched at PubMed (from inception to 31 January 2018) to identify clinical studies that assessed the prevalence of cachexia in cancer patients at risk. Studies reporting the prevalence of either cancer cachexia or wasting disease in the top‐10 cancer types and 4 other selected cancer types known to be particularly commonly complicated by cachexia were included in this analysis (i.e. prostate cancer, breast cancer, colorectal cancer, melanoma, endometrial cancer, thyroid cancer, urinary bladder cancer, non‐hodgkin lymphoma, lung cancer, kidney and renal pelvis cancer, head and neck cancer, gastric cancer, liver cancer, and pancreatic cancer). We calculated the current burden of cancer cachexia, disease by disease, in the USA and in the EU and compared them to the current guidelines for the definition of orphan disease status. Results We estimate that in 2014 in the USA, a total of 527 100 patients (16.5 subjects per 10 000 people of the total population), and in 2013 in the EU, a total of 800 300 patients (15.8 subjects per 10 000 people of the total population) suffered from cancer cachexia (of any kind). In the 14 separately analysed cancer types, the prevalence of cancer cachexia in the USA ranged between 11 300 (0.4/10 000, gastric cancer) and 92 000 patients (2.9/10 000, lung cancer) and in the EU between 14 300 (0.3/10 000, melanoma of the skin) and 150 100 (3.0/10 000, colorectal cancer). Conclusions The absolute number of patients affected by cancer cachexia in each cancer group is lower than the defined thresholds for orphan diseases in the USA and EU. Cancer cachexia in each subgroup separately should be considered an orphan disease.
Methodological consensus on clinical proton MRS of the brain: Review and recommendations
Wilson, Martin , Andronesi, Ovidiu C. , Barker, Peter B. , Bartha, Robert , Bizzi, Alberto , Bolan, Patrick J. , Cudalbu, Cristina , Dydak, Ulrike , Emir, Uzay E. , González, R. Gilberto , Gruber, Stephan , Gupta, Rakesh K. , Henning, A , Hetherington, Hoby P. , Hüppi, Petra S. , Hurd, Ralph E. , Kantarci, Kejal , Kauppinen, Risto A. , Klomp, Dennis W. J. , Kreis, Roland , Kruiskamp, Marijn J., Leach, Martin O. , Lin, Alexander , Luijten, Peter R. , Marjańska, Małgorzata , Meyerhoff, Dieter J. , Mountford, Carolyn E. , Mullins, Paul G. , Murdoch, James B. , Nelson, Sarah J. , Noeske, Ralph , Öz, Gülin , Pan, Julie W., Poptani, Harish , Posse, Stefan , Ratai, Eva‐Maria , Salibi, Nouha , Scheenen, Tom W. J. , Soher, Brian J. , Tkáč, Ivan , Vigneron, Daniel B. , Howe, Franklyn A. , Choi, In‐Young , Kreis, Roland , Maudsley, Andrew A , Howe, Franklyn A , Öz, Gülin , Marjańska, Małgorzata , Kantarci, Kejal , Brindle, Kevin Michael , Choi, In‐Young, Gruetter, Rolf , Heerschap, Arend , Peet, Andrew C. , Smith, Ian C. P.

Mayo Clinic

Magnetic Resonance in Medicine | March 28, 2019 | Volume: 82 | Issue: 2 | Pages: 527-550

10.1002/mrm.27742 | PMID 30919510 Get It

Proton MRS (1H MRS) provides noninvasive, quantitative metabolite profiles of tissue and has been shown to aid the clinical management of several brain diseases. Although most modern clinical MR scanners support MRS capabilities, routine use is largely restricted to specialized centers with good access to MR research support. Widespread adoption has been slow for several reasons, and technical challenges toward obtaining reliable good‐quality results have been identified as a contributing factor. Considerable progress has been made by the research community to address many of these challenges, and in this paper a consensus is presented on deficiencies in widely available MRS methodology and validated improvements that are currently in routine use at several clinical research institutions. In particular, the localization error for the PRESS localization sequence was found to be unacceptably high at 3 T, and use of the semi‐adiabatic localization by adiabatic selective refocusing sequence is a recommended solution. Incorporation of simulated metabolite basis sets into analysis routines is recommended for reliably capturing the full spectral detail available from short TE acquisitions. In addition, the importance of achieving a highly homogenous static magnetic field (B0) in the acquisition region is emphasized, and the limitations of current methods and hardware are discussed. Most recommendations require only software improvements, greatly enhancing the capabilities of clinical MRS on existing hardware. Implementation of these recommendations should strengthen current clinical applications and advance progress toward developing and validating new MRS biomarkers for clinical use.
Pharmacological clearance of senescent cells improves survival and recovery in aged mice following acute myocardial infarction
Walaszczyk, Anna , Dookun, Emily , Redgrave, Rachael E. , Tual‐Chalot, Simon , Victorelli, Stella , Spyridopoulos, Ioakim , Owens, W. Andrew , Arthur, Helen M. , Passos, João F. , Richardson, Gavin D. , Spyridopoulos, Ioakim , Arthur, Helen M , Passos, João F , Richardson, Gavin D

Mayo Clinic

Aging Cell | March 28, 2019 | Volume: 18 | Issue: 3 | Pages: No page available

10.1111/acel.12945 | PMID 30920115 Get It

Abstract Cardiovascular disease is the leading cause of death in individuals over 60 years old. Aging is associated with an increased prevalence of coronary artery disease and a poorer prognosis following acute myocardial infarction (MI). With age, senescent cells accumulate in tissues, including the heart, and contribute to age‐related pathologies. However, the role of senescence in recovery following MI has not been investigated. In this study, we demonstrate that treatment of aged mice with the senolytic drug, navitoclax, eliminates senescent cardiomyocytes and attenuates profibrotic protein expression in aged mice. Importantly, clearance of senescent cells improved myocardial remodelling and diastolic function as well as overall survival following MI. These data provide proof‐of‐concept evidence that senescent cells are major contributors to impaired function and increased mortality following MI and that senolytics are a potential new therapeutic avenue for MI.
The utility of prognostic indices, early events, and histological subtypes on predicting outcomes in non‐follicular indolent B‐cell lymphomas
Tracy, Sean , Novak, Anne J. , Allmer, Cristine, Farooq, Umar , Syrbu, Sergei , Link, Brian K. , Tracy, Sean I , Cerhan, James R , Link, Brian K , Farooq, Umar , Syrbu, Sergei , Larson, Melissa C. , Feldman, Andrew L. , Maurer, Matthew J. , Slager, Susan L. , Villasboas, José C. , Habermann, Thomas M. , Cerhan, James R.

Mayo Clinic

American Journal of Hematology | March 28, 2019 | Volume: 94 | Issue: 6 | Pages: 658-666

10.1002/ajh.25473 | PMID 30916801 Get It

AbstractIndolent B‐cell lymphomas other than follicular lymphoma account for up to 10% of all B‐cell neoplasms. While they typically follow a slowly progressive course, some patients experience rapid progression and early mortality. Prognostic scoring systems have not been adopted, hindering the ability of clinicians or researchers to predict outcomes, or risk‐stratify patients during clinical trials. To address this, we evaluated the utility of existing prognostic indices and novel, early disease‐related outcomes, to predict subsequent long term survival. Baseline characteristics and outcomes data were generated from a longitudinal cohort study that prospectively enrolled 632 patients newly diagnosed with marginal zone lymphoma, lymphoplasmacytic lymphomas, or B‐cell lymphomas not otherwise specified, beginning in 2002. The International Prognostic Index (IPI), Follicular Lymphoma International Prognostic Index (FLIPI), and MALT International prognostic index (MALT‐IPI) demonstrated c‐statistics that ranged from 0.593‐0.612 for event‐free survival (EFS), and 0.683‐0.714 for overall survival (OS). Patients who attained event‐free survival at 12 months (EFS12) experienced similar mortality to the US general population (standardized mortality ratio [SMR] 1.19; 95% CI 0.95‐1.46). Patients who did not attain EFS12 had subsequent worse morality (SMR 3.14 (95% CI 2.05‐4.59). The MALT‐IPI demonstrated utility in predicting subsequent long‐term outcomes among patients with non‐follicular indolent B‐cell lymphomas. This index should be used by clinicians giving guidance to patients at the time of initial diagnosis, and risk stratification during clinical studies. The divergent long‐term outcomes experienced by patients who do or do not attain EFS12 suggest there exists a subset of patients who harbor high‐risk disease. Future research efforts should focus on methods to identify these patients at the time of diagnosis, in order to enable risk‐tailored therapy.